Tilray Brands (NASDAQ:TLRY) Trading 6.7% Higher After Analyst Upgrade

Tilray Brands, Inc. (NASDAQ:TLRY) shot up 6.7% during trading on Thursday after Roth Mkm upgraded the stock from a neutral rating to a buy rating. Roth Mkm now has a $10.00 price target on the stock. Tilray Brands traded as high as $6.66 and last traded at $6.55. 5,508,183 shares were traded during trading, an increase of 49% from the average session volume of 3,697,357 shares. The stock had previously closed at $6.14.

Other analysts have also issued research reports about the stock. Wall Street Zen raised shares of Tilray Brands from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tilray Brands in a report on Wednesday, January 21st. Canaccord Genuity Group began coverage on shares of Tilray Brands in a research note on Tuesday, January 27th. They issued a “hold” rating for the company. TD Cowen lowered their target price on shares of Tilray Brands from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, March 30th. Finally, ATB Cormark Capital Markets upgraded Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 10th. Three equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Tilray Brands presently has a consensus rating of “Hold” and a consensus price target of $11.20.

Key Tilray Brands News

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Roth/MKM upgraded TLRY to Buy (new $10 price target), citing the Q3 results as a catalyst for improved sentiment—this upgrade supports near-term buying interest. Roth upgrade coverage
• Positive Sentiment: Jefferies reiterated a Buy and kept a $24 price target, pointing to strong cannabis sales and better medium‑term visibility; a high PT from a major shop increases upside narratives for investors. Jefferies note
• Positive Sentiment: Regulatory tailwind: reports that the FDA won’t enforce some CBD regulations spurred sector buying, lifting Tilray alongside peers and improving the outlook for CBD revenue. FDA/CBD coverage
• Positive Sentiment: Product/brand news — Tilray Beverages’ Shock Top launched a high‑ABV beer (High Voltage), a growth/innovation signal for the beverages segment that can help top-line recovery over time. Shock Top launch
• Neutral Sentiment: Analyst/deep-dive pieces see TLRY as improving but still mixed: commentary highlights revenue growth, international cannabis up ~73% in Q3, and narrowing losses but cautions on margins, cash flow and M&A execution. This frames TLRY as a recovery story with execution risk. Seeking Alpha analysis
• Neutral Sentiment: Zacks and other commentary call Q3 mixed—revs beat slightly and losses narrowed, but beverage weakness and margin pressure temper bullish cases. Zacks piece
• Negative Sentiment: Earnings miss: TLRY reported Q3 EPS of -$0.24 vs. consensus -$0.14 (revenue ~$206.7M vs. est. ~$201.4M). The EPS shortfall on the call raised concerns about margins and profitability despite top-line improvements. MSN earnings transcript InsiderMonkey transcript
• Negative Sentiment: ATB Cormark trimmed its price target to $9.00 and moved to sector perform, signaling more conservative near‑term expectations and adding selling pressure from cautious analysts. ATB Cormark note

Hedge Funds Weigh In On Tilray Brands

Several institutional investors and hedge funds have recently made changes to their positions in TLRY. Silverlake Wealth Management LLC bought a new stake in Tilray Brands in the third quarter worth $25,000. Oppenheimer & Co. Inc. bought a new position in shares of Tilray Brands during the third quarter valued at about $25,000. Unified Investment Management bought a new position in shares of Tilray Brands during the third quarter valued at about $26,000. J.W. Cole Advisors Inc. increased its holdings in shares of Tilray Brands by 203.2% in the second quarter. J.W. Cole Advisors Inc. now owns 71,890 shares of the company’s stock worth $30,000 after buying an additional 48,177 shares during the period. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of Tilray Brands in the third quarter worth about $30,000. Institutional investors own 9.35% of the company’s stock.

Tilray Brands Stock Performance

The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.72 and a current ratio of 2.79. The business has a 50 day moving average price of $7.27 and a two-hundred day moving average price of $10.19. The company has a market cap of $763.14 million, a P/E ratio of -0.48 and a beta of 2.00.

Tilray Brands (NASDAQ:TLRY) last issued its earnings results on Wednesday, April 1st. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.10). Tilray Brands had a negative net margin of 156.51% and a negative return on equity of 3.31%. The company had revenue of $206.73 million for the quarter, compared to analysts’ expectations of $201.35 million. During the same quarter in the prior year, the company earned ($0.87) earnings per share. On average, sell-side analysts anticipate that Tilray Brands, Inc. will post -0.2 earnings per share for the current year.

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.